for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Helius Medical Technologies Inc

HSDT.OQ

Latest Trade

0.87USD

Change

-0.02(-2.06%)

Volume

1,570

Today's Range

0.85

 - 

0.90

52 Week Range

0.80

 - 

10.67

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.88
Open
0.90
Volume
1,570
3M AVG Volume
0.70
Today's High
0.90
Today's Low
0.85
52 Week High
10.67
52 Week Low
0.80
Shares Out (MIL)
25.90
Market Cap (MIL)
27.16
Forward P/E
1.75
Dividend (Yield %)
--

Latest Developments

More

Helius Says FDA Indicated That More Data Is Required To Support Application Submission

Helius Medical Technologies Says Q2 Loss Per Share $0.01

Helius Medical Provides Update On FDA Strategy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Helius Medical Technologies Inc

Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain's ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device. The device, when used in combination with physiotherapy, is designed to enhance the brain's ability to compensate for damage due to trauma or disease. The Company's PoNS device is designed to induce cranial nerve non-invasive neuromodulation through an increase in stimulation of the facial and trigeminal nerves, which innervate the tongue. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation. The PoNS device is an electrical pulse generator that delivers controlled electrical stimulation to the tongue.

Industry

Medical Equipment & Supplies

Contact Info

642 Newtown Yardley Rd

+1.215.9446104

http://www.heliusmedical.com/

Executive Leadership

Philippe Deschamps

Chairman of the Board, President, Chief Executive Officer, Director

Joyce N. LaViscount

Chief Financial Officer, Chief Operating Officer

Jonathan Sackier

Chief Medical Officer

Mitchell Eugene Tyler

Director

Dane C. Andreeff

Independent Director

Key Stats

3.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.020

2018

-1.260

2019(E)

-0.397
Price To Earnings (TTM)
--
Price To Sales (TTM)
16.24
Price To Book (MRQ)
2.13
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-1,324.08
Return on Equity (TTM)
-48.15

Latest News

Latest News

BRIEF-Helius Medical - If Co Fails To Ensure Commercialization Of Pons Treatment Is Available For U.S. Government By Dec. 31, 2021, Co May Forfeit Right To Pursue Commercialization

* HELIUS MEDICAL TECHNOLOGIES - IF CO FAILS TO ENSURE COMMERCIALIZATION OF PONS TREATMENT IS AVAILABLE FOR U.S. GOVERNMENT BY DEC. 31, 2021, CO MAY FORFEIT RIGHT TO PURSUE COMMERCIALIZATION

BRIEF-Helius Medical Technologies Announces Uplisting To Nasdaq And Pricing Of Public Offering Of Class A Common Stock And Warrants

* HELIUS MEDICAL TECHNOLOGIES, INC. ANNOUNCES UPLISTING TO NASDAQ AND PRICING OF PUBLIC OFFERING OF CLASS A COMMON STOCK AND WARRANTS

BRIEF-Helius Medical says launched 6th site for brain injury trial

* Helius Medical Technologies announces launch of sixth site for pivotal mild to moderate traumatic brain injury clinical trial Source text for Eikon: Further company coverage:

BRIEF-Helius Medical Technologies files for mixed shelf of up to $100 mln - SEC filing

* May use a portion of net proceeds to invest,acquire businesses,technologies we believe are complementary Source text: (http://bit.ly/2i1SNQX) Further company coverage:

BRIEF-Helius Medical reached full enrollment in tactile communication and neurorehabilitation laboratory clinical trial

* Full enrollment reached in tactile communication and neurorehabilitation laboratory clinical trial

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up